UNSPSC 51411616: Tipropidil hydrochloride

This classification denotes a vasodilating agent with the molecular formula C20H35NO2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34K00NS0TZ, chemically known as 2-propanol, 1-(4-((1-methylethyl)thio)phenoxyl)-3-(octylamino)-, hydrochloride but more generally known as tipropidil hydrochloride, which bears US NIH Compound Identifier 72175. Most nations, for tariff and trade purposes, schedule tipropidil hydrochloride under HS 29309085 and SITC 51549.

As of Q4 2014, TIPROPIDIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tipropidil hydrochloride bears US NLM identifiers UMLS ID C0145972 and NCI Concept Code C77079. SMILES: CCCCCCCCNCC(COC1CCC(CC1)SC(C)C)O.CL.

UNSPSC 51411616 Tipropidil hydrochloride, a Commodity code, covers pharmaceutical active pharmaceutical ingredients and finished medications supplied to state and local health agencies, emergency response services, and multi-state cooperative purchasing programs. State and local governments procure under this code primarily for emergency medical services, public health programs, and institutional healthcare delivery. Recent solicitations show demand for advanced life support medications, generic pharmaceuticals, and over-the-counter products distributed through state health agencies, fire rescue departments, and multi-state cooperative purchasing vehicles.

The issuing bodies include municipal fire and rescue departments (City of Tampa), state health commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Oregon). Representative recent opportunities include the City of Tampa Fire Rescue's sealed-bid procurement (No. 26P00188) for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with a response deadline of April 8, 2026 and estimated contract value of $40,000; the Texas HHS Commission's Request for Information (No. HHS0017013) soliciting vendor capabilities for a Direct-to-Manufacturer Prescriptions program, posted April 3, 2026; and the Minnesota Department of Administration's multi-state RFP (No. S1070000015802) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, covering state and local facilities across Minnesota and Oregon through authorized wholesalers. Activity concentrates in Florida, Texas, and Minnesota, with multi-state reach through cooperative purchasing mechanisms. The Tampa procurement includes a 5 percent bid discount for Small Local Business Enterprise participation and requires all materials to meet OSHA Hazard Communication Standards and FDA compliance with minimum nine-month expiration dates upon acceptance.